Description

Actovegin (5 ampoules) 40 mg/ml. 

Indications:

Metabolic and vascular disorders in the brain, such as

cerebral insufficiency syndrome, ischemic strokes, or traumatic brain injury, can be treated with indications of this type.

In addition, treatments for peripheral (arterial and venous) vascular disorders and their consequences (such as arterial angiopathy and crus ulcers) can be beneficial.

Wound healing for ulcers of various etiologies, trophic disorders, and secondary healing processes can also be addressed.

Other indications include skin transplantations, thermal and chemical burns, radiation damage to the skin, mucous membranes, and nervous tissue, as well as hypoxia and ischemia of various organs and tissues, and their consequences.

Contraindications: Pulmonary edema; oliguria; anuria; fluid retention; decompensated heart failure (solution for infusions); hypersensitivity to the drug.

Doses and route of administration depend on the indications and the severity of the disease.

• The solution for injection is administered intramuscularly, intravenously or intraarterially. Depending on the severity of the course of the disease, 10-20 ml of the injection solution is initially injected intravenously or intraarterially, and further 5 ml are administered intravenously (slowly) or intramuscularly daily or several times a week.
• In circulatory disorders and metabolism of the brain, initially, 10 ml is administered intravenously daily for 2 weeks, followed by the 5-10 ml intravenous administration several times a week for 4 weeks.
• In ischemic stroke, 20-50 ml is diluted in 200-300 ml of infusion solution and administered intravenously daily or several times a week for 2-3 weeks.
• In arterial angiopathy, 20-50 ml are diluted in an infusion solution and injected intraarterially or intravenously daily or several times a week. The average duration of treatment is 4 weeks.
• For trophic and other sluggish ulcers, burns, 10 ml are injected intravenously or 5 ml intramuscularly daily or several times a day, depending on the severity of the lesion, as a supplement to local therapy with Actovegin.
• The injection solution can be administered either intramuscularly, intravenously, or intraarterially, depending on the severity of the disease. For circulatory disorders and metabolic issues in the brain, 10 ml is administered intravenously daily for two weeks, followed by 5-10 ml intravenously several times a week for the next four weeks.

In the event of an ischemic stroke, 20-50 ml should be diluted in 200-300 ml of infusion solution and injected intravenously daily or several times a week for two to three weeks.

For arterial angiopathy, 20-50 ml should be diluted in an infusion solution and injected either intraarterially or intravenously daily or several times a week, with the average duration of treatment being four weeks.

Lastly, for trophic and other sluggish ulcers or burns, 10 ml should be injected intravenously or 5 ml intramuscularly daily or several times a day in conjunction with local therapy with Actovegin.

In order to prevent and treat radiation lesions of the skin and mucous membranes, an average of 5 ml is administered intravenously daily in the intervals between radiation exposure.

Actovegin 40 mg/ml is administered transurethrally in the form of an injection solution with an active substance content of 400 mg / 10 ml for cystitis due to radiation, 10 ml daily in combination with antibacterial therapy.

Solution for infusion of 20% in sodium chloride solution, solution for infusion of 10% in sodium chloride solution, solution for infusion of 10% in dextrose solution are administered intravenously by drop infusion or intraarterially by bolus injection.

In case of disorders of the blood supply and metabolism of the brain, 250–500 ml/day intravenous injection is first administered for 2 weeks, then 250 ml intravenously several times a week for at least 4 weeks.

In ischemic stroke, 250-500 ml is administered intravenously daily or several times a week for about 2-3 weeks.

In arterial angiopathy, 250 ml is administered intraarterially and intravenously daily or several times a week; the duration of therapy is about 4 weeks.

For trophic and other slow-shedding ulcers, burns, 250 ml is administered intravenously daily or several times a week, depending on the healing, in addition to Actovegin therapy for external use.

In order to prevent and treat radiation lesions of the skin and mucous membranes, an average of 250 ml is administered intravenously one day before the start and every day during radiation therapy, as well as within 2 weeks after its termination.

Guidelines for the introduction of solutions

It is recommended to inject no more than 5 ml intramuscularly.

Actovegin solutions for injections are compatible with isotonic sodium chloride solution and 5% dextrose solution (base solutions). For the infusion, 10-50 ml of the solution for injection is diluted in 200-300 ml of the base solution. The infusion rate is about 2 ml per minute.

Check also Discussions page